S&P 500   3,327.45 (+1.72%)
DOW   26,782.79 (+0.99%)
QQQ   278.52 (+2.53%)
AAPL   116.41 (+4.69%)
MSFT   206.41 (+1.84%)
FB   281.00 (+4.98%)
GOOGL   1,574.19 (+4.20%)
AMZN   3,233.39 (+2.23%)
TSLA   414.51 (+2.09%)
NVDA   524.24 (+3.79%)
BABA   315.34 (+2.40%)
CGC   18.84 (+2.73%)
GE   7.38 (-0.54%)
MU   50.70 (+1.40%)
AMD   78.49 (+2.74%)
T   26.85 (+1.32%)
F   7.93 (+2.99%)
ACB   4.04 (+5.48%)
GILD   58.81 (+0.15%)
NFLX   509.29 (+4.74%)
NIO   31.80 (+15.59%)
BA   148.29 (+0.10%)
DIS   121.98 (+2.96%)
S&P 500   3,327.45 (+1.72%)
DOW   26,782.79 (+0.99%)
QQQ   278.52 (+2.53%)
AAPL   116.41 (+4.69%)
MSFT   206.41 (+1.84%)
FB   281.00 (+4.98%)
GOOGL   1,574.19 (+4.20%)
AMZN   3,233.39 (+2.23%)
TSLA   414.51 (+2.09%)
NVDA   524.24 (+3.79%)
BABA   315.34 (+2.40%)
CGC   18.84 (+2.73%)
GE   7.38 (-0.54%)
MU   50.70 (+1.40%)
AMD   78.49 (+2.74%)
T   26.85 (+1.32%)
F   7.93 (+2.99%)
ACB   4.04 (+5.48%)
GILD   58.81 (+0.15%)
NFLX   509.29 (+4.74%)
NIO   31.80 (+15.59%)
BA   148.29 (+0.10%)
DIS   121.98 (+2.96%)
S&P 500   3,327.45 (+1.72%)
DOW   26,782.79 (+0.99%)
QQQ   278.52 (+2.53%)
AAPL   116.41 (+4.69%)
MSFT   206.41 (+1.84%)
FB   281.00 (+4.98%)
GOOGL   1,574.19 (+4.20%)
AMZN   3,233.39 (+2.23%)
TSLA   414.51 (+2.09%)
NVDA   524.24 (+3.79%)
BABA   315.34 (+2.40%)
CGC   18.84 (+2.73%)
GE   7.38 (-0.54%)
MU   50.70 (+1.40%)
AMD   78.49 (+2.74%)
T   26.85 (+1.32%)
F   7.93 (+2.99%)
ACB   4.04 (+5.48%)
GILD   58.81 (+0.15%)
NFLX   509.29 (+4.74%)
NIO   31.80 (+15.59%)
BA   148.29 (+0.10%)
DIS   121.98 (+2.96%)
S&P 500   3,327.45 (+1.72%)
DOW   26,782.79 (+0.99%)
QQQ   278.52 (+2.53%)
AAPL   116.41 (+4.69%)
MSFT   206.41 (+1.84%)
FB   281.00 (+4.98%)
GOOGL   1,574.19 (+4.20%)
AMZN   3,233.39 (+2.23%)
TSLA   414.51 (+2.09%)
NVDA   524.24 (+3.79%)
BABA   315.34 (+2.40%)
CGC   18.84 (+2.73%)
GE   7.38 (-0.54%)
MU   50.70 (+1.40%)
AMD   78.49 (+2.74%)
T   26.85 (+1.32%)
F   7.93 (+2.99%)
ACB   4.04 (+5.48%)
GILD   58.81 (+0.15%)
NFLX   509.29 (+4.74%)
NIO   31.80 (+15.59%)
BA   148.29 (+0.10%)
DIS   121.98 (+2.96%)
Log in
NASDAQ:RNLX

Renalytix AI Stock Forecast, Price & News

$12.09
+0.05 (+0.42 %)
(As of 10/28/2020 12:00 AM ET)
Add
Compare
Today's Range
$11.24
Now: $12.09▼
$12.25
50-Day Range
$10.18
MA: $12.20▼
$14.35
52-Week Range
$9.91
Now: $12.09▼
$18.00
Volume6,157 shs
Average Volume60,881 shs
Market Capitalization$435.42 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform, which employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.15 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:RNLX
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.renalytixai.com
Phone44-20-3139-2910
Employees12

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares36,015,000
Market Cap$435.42 million
Next Earnings DateN/A
OptionableNot Optionable
$12.09
+0.05 (+0.42 %)
(As of 10/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RNLX News and Ratings via Email

Sign-up to receive the latest news and ratings for RNLX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Renalytix AI (NASDAQ:RNLX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Renalytix AI?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Renalytix AI in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Renalytix AI.

What price target have analysts set for RNLX?

2 analysts have issued twelve-month target prices for Renalytix AI's stock. Their forecasts range from $22.00 to $22.00. On average, they anticipate Renalytix AI's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 82.0% from the stock's current price.
View analysts' price targets for Renalytix AI.

Who are some of Renalytix AI's key competitors?

Some companies that are related to Renalytix AI include Genetron (GTH), Castle Biosciences (CSTL), Personalis (PSNL), RadNet (RDNT), Fulgent Genetics (FLGT), Progenity (PROG), DermTech (DMTK), Centogene (CNTG), Exagen (XGN), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Celcuity (CELC), Biocept (BIOC), OpGen (OPGN) and Anpac Bio-Medical Science (ANPC).
View all competitors.

What other stocks do shareholders of Renalytix AI own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix AI investors own include Ampio Pharmaceuticals (AMPE), Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CorMedix (CRMD), CTI BioPharma (CTIC), DRDGOLD (DRD), Equinox Gold Cp (EQX) and Forte Biosciences (FBRX).

Who are Renalytix AI's key executives?

Renalytix AI's management team includes the following people:
  • Mr. James R. McCullough M.B.A., CEO & Director (Age 52, Pay $215.76k)
  • Mr. Fergus Fleming, CTO & Director (Age 53, Pay $671.95k)
  • Mr. Thomas H. McLain, Pres & Chief Commercial Officer (Age 61)
  • Mr. Oliver James Sterling III, Chief Financial Officer
  • Dr. Sally Bowden, Head of Regulatory Affairs & CBO (Age 50)
  • Mr. Baljit Singh, Head of Clinical Operations
  • Dr. Michael J. Donovan, Chief Medical Officer (Age 65)
  • Salim Hamir, Company Sec.

When did Renalytix AI IPO?

(RNLX) raised $156 million in an initial public offering on Friday, July 17th 2020. The company issued 11,000,000 shares at a price of $14.22 per share. J.P. Morgan and Stifel served as the underwriters for the IPO.

What is Renalytix AI's stock symbol?

Renalytix AI trades on the NASDAQ under the ticker symbol "RNLX."

When does the company's lock-up period expire?

Renalytix AI's lock-up period expires on Wednesday, January 13th. Renalytix AI had issued 5,485,000 shares in its initial public offering on July 17th. The total size of the offering was $74,047,500 based on an initial share price of $13.50. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

How do I buy shares of Renalytix AI?

Shares of RNLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Renalytix AI's stock price today?

One share of RNLX stock can currently be purchased for approximately $12.09.

How big of a company is Renalytix AI?

Renalytix AI has a market capitalization of $435.42 million. Renalytix AI employs 12 workers across the globe.

What is Renalytix AI's official website?

The official website for Renalytix AI is www.renalytixai.com.

How can I contact Renalytix AI?

Renalytix AI's mailing address is AVON HOUSE 19 STANWELL ROAD PENARTH, CARDITH X0, CF64 2EZ. The company can be reached via phone at 44-20-3139-2910 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.